What is TB-500?
TB-500 commonly refers to a fragment associated with thymosin beta-4 biology. Evidence for full-length thymosin beta-4 should not automatically be attributed to TB-500.
Proposed mechanism
Research interest comes from thymosin beta-4 pathways involving actin, cell migration, angiogenesis and tissue remodelling.
What has been published?
Full-length thymosin beta-4 has preclinical and human wound-healing research, while the evidence for the TB-500 fragment is much thinner.
Current human evidence
FDA states that it has not identified human exposure data for drug products containing the thymosin beta-4 fragment identified as TB-500.
Regulatory status
TB-500 is not an FDA-approved medicine. FDA lists it among substances that may present significant safety risks in compounding.
Possible areas of research interest
- Cell migration
- Wound-healing biology
- Angiogenesis
- Actin signalling
Important limitations
- TB-500 and full-length thymosin beta-4 are not interchangeable evidence bases
- No established human efficacy data for TB-500
- Product identity and purity can be difficult to verify
- Potential immunogenicity and impurity concerns remain
References
AEVLI prioritizes primary publications and regulator materials over anecdotal claims.